Drug Discovery World
FEBRUARY 19, 2024
Preclinical data has demonstrated insulin independence following transplantation of hypoimmune (HIP) allogeneic primary islet cells without immunosuppression in a diabetic non-human primate (NHP). Following this, blood glucose levels in the diabetic NHP began to fluctuate and increase markedly, and insulin injections needed to be resumed.
XTalks
NOVEMBER 22, 2022
Type 1 diabetes, also known as insulin-dependent or juvenile diabetes, is an autoimmune disease that occurs when the body is unable to make enough insulin due to destruction of the beta insulin-producing cells in the pancreas. In the US, it is estimated that 1.45 million people are currently living with type 1 diabetes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
AUGUST 17, 2020
Monoclonal antibodies : these are antibodies that are designed to bind to specific targets on cells. Treatment vaccines : these boost the immune system responses to target cells. Immune system modulators (i.e. receptors) of the immune system to enhance, or suppress immune responses.
The Pharma Data
AUGUST 3, 2021
Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. The trial compared tirzepatide to insulin glargine in adults with type 2 diabetes and increased cardiovascular risk. Loxo Oncology at Lilly and Kumquat Biosciences Inc.
The Pharma Data
DECEMBER 31, 2020
Antibodies Respond Differently to Severe Versus Mild COVID-19. Researchers at Stanford Medicine found that COVID-19 antibodies preferentially target different parts of the SARS-CoV-2 virus in mild COVID-19 cases than they do in severe cases. People with severe COVID-19 have low proportions of antibodies that target the spike protein.
Drug Discovery World
SEPTEMBER 6, 2022
CellTrans is currently awaiting an FDA decision for its cell therapy Lantidra, a treatment for patients with brittle type 1 diabetes mellitus whose symptoms cannot be well managed despite insulin therapy.
XTalks
SEPTEMBER 17, 2020
Acromegaly Surrogate Endpoint: Serum growth hormone and serum insulin-like growth factor 1 (IGF-1) are acceptable surrogate endpoints for acromegaly clinical trials involving somatostatin analogs such as octreotide, lanreotide and pasireotide. Also known as Berardinelli-Seip syndrome, there are four subtypes of lipodystrophy.
Expert insights. Personalized for you.
52 
Let's personalize your content